Left ventricular hypertrophy (LVH) is prevalent and associated with a poor long-term prognosis. The Framingham Heart Study, for example, showed that LVH was present in 15–20% of adults, and that, for each 50 g/m² increment of left ventricular mass, the relative risk of cardiovascular death increased by 1.73 in men and 2.12 in women.1 Although hypertension, obesity and valvulopathies account for most causes of LVH, it is important to investigate patients with otherwise unexplained LVH since many causes are treatable.

Practical approach to the evaluation of left ventricular hypertrophy

Although several electrocardiographic (ECG) criteria for the identification of LVH are available, additional investigations (notably transthoracic echocardiography (echo)) are invariably required due to the lack of sensitivity and specificity of ECG. The European Association of Echocardiography definition of LVH includes the demonstration of interventricular septal and/or posterior wall thickness in end-diastole ≥ 13 mm.2 Echocardiography can additionally interrogate valve function and characterize LVH as concentric (uniform mechanism, e.g. LV pressure overload, myocardial infiltration), or eccentric [e.g. asymmetrical septal hypertrophy in hypertrophic cardiomyopathy (HCM)].

After the identification of LVH, a practical approach to its further assessment includes a clinical review with targeted investigations aimed firstly to exclude common causes; e.g. hypertension, obesity and valve disease. Thereafter, evaluation involves a systematic approach to exclude less common causes, e.g. hypertrophic and other cardiomyopathies, myocardial infiltration, metabolic disorders, and syndromic conditions associated with LVH.

Hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy has been defined as a hypertrophied, non-dilated LV in the absence of another systemic or cardiac process capable of producing LVH.3,4 Hypertrophic cardiomyopathy is the most common genetically determined cardiomyopathy with an estimated clinical prevalence in the population of 1:500.4 In most cases, HCM is autosomal dominantly transmitted through mutations in one of several cardiac sarcomeric genes.3 Recent progresses in molecular genetics have generated interest in adopting a genetics-based HCM classification.4 However, the European classification of hypertrophic, dilated, arrhythmogenic right ventricular, restrictive non-hypertrophied, and unclassified forms of cardiomyopathy based on clinical, haemodynamic, and structural features may be more practical.5 This is particularly relevant since in many cases genotype–phenotype correlations remain elusive.

Although criteria for the diagnosis of HCM are described,3 several secondary forms of concentric LVH exist. A screening study among 508 ‘HCM’ patients, for example, found that ~1%...
### Table 1  Clinical characteristics of conditions causing left ventricular hypertrophy and diagnostic pointers

| Condition                | Clinical pearls                                                                 | Diagnostic pointers                                                                 |
|--------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| **Common causes**        |                                                                                 |                                                                                      |
| Hypertension             | *~15%: secondary cause*                                                        | ECG: LVH (prevalence ~30%) can predict prognosis                                      |
|                          | Fundoscopic changes                                                            | Echo: concentric LVH                                                                |
|                          | Lost nocturnal dip on 24 h recording                                            | CMR: may help identify aortic coarctation                                           |
|                          | 60%: ≥2 hypotensives needed to achieve control                                 | Genetics: not useful as polygenetic influences                                       |
|                          |                                                                                | Laboratory: to exclude secondary causes                                              |
|                          |                                                                                | Others: 24 h ambulatory monitoring                                                   |
| Aortic stenosis          | *Slow rising pulse*                                                            | ECG: LVH                                                                            |
|                          | *Ejection systolic murmur*                                                      | Echo: the trans-aortic valve gradient and the reduced valve area (beware sub-aortic membranes) |
|                          | *Soft second heart sound*                                                       | CMR: nil specific                                                                   |
|                          |                                                                                | Genetics: nil specific                                                               |
|                          |                                                                                | Laboratory: nil specific                                                             |
| Obesity                  | *Body mass index*                                                               | ECG: attenuated LVH due to body habitus (prevalence ~10%)                           |
|                          | *Waist circumference*                                                           | Echo: concentric LVH. Epididymal fat can predict prognosis                          |
|                          | *LVH regression with weight loss*                                               | CMR: useful if poor echo windows                                                    |
|                          |                                                                                | Genetics: monogenic disorders of body fat, e.g. leptin deficiency                   |
|                          |                                                                                | Laboratory: endocrine causes, e.g. diabetes, thyroid, pituitary, adrenal             |
| Physiological LVH        | *High level endurance training*                                                 | ECG: LVH                                                                            |
| Athletic heart           | *Resting bradycardia*                                                           | Echo: mild concentric LVH (rarely >13 mm) and volume-loaded (dilated) LV cavity.   |
|                          | *LVH regression with deconditioning*                                           | Preserved diastolic and long-axis function                                           |
| Sarcomere protein        | *Family history (population prevalence 1:500)*                                 | CMR: no late gadolinium enhancement                                                 |
| disease                  | *Leading cause of sudden death in young athletes*                              | Genetics: nil specific                                                               |
| Hypertrophic cardiomyopathy | *Risk stratification for sudden cardiac death*                                | Laboratory: nil specific                                                             |
|                          |                                                                                | Others: VO2 max > predicted                                                         |
| Myocardial infiltration  | Senile amyloid relatively common (20% of over 80 year olds)                    |                                                                          |
| Amyloidosis              | Multi-system involvement with variable signs including: proteinuria, petechiae, peripheral, and autonomic neuropathy, hepato-splenomegaly, macroglossia | ECG: paradoxical low voltage QRS complexes, heart block, atrial fibrillation        |
|                          | Echo: LVH with preserved LV size and bi-atrial dilatation.                      | Echo: LVH                                                                           |
|                          | Granular LV appearance (low sensitivity). Restrictive physiology, and thickened inter-atrial septum and valve leaflets | CMR: global sub-endocardial late gadolinium enhancement                              |
|                          | Global LV dimensions in early stages of disease.                                | Genetics: transthyretin gene testing (autosomal dominant)                            |
|                          | Systolic anterior motion of mitral valve, dilated left atrium, diastolic dysfunction, and dynamic LV outflow tract obstruction | Laboratory: cross speciality investigations to differentiate between various forms of amyloid |
|                          | CMR: intra-myocardial late gadolinium enhancement                               | Other: Congo red staining of target organ biopsies                                   |
|                          | Genetics: autosomal dominant                                                    | Others: endomyocardial biopsy: triad of myocyte and myofibril disarray, myocardial fibrosis, and small vessel disease |
| Haemo-chromatosis         | Late presentation in females                                                     | ECG: LVH                                                                            |
|                          | Transfusion overload                                                            | Echo: LVH with bi-ventricular and bi-atrial dilatation.                             |
|                          | Clinical constellation includes bronze skin, arthritis, diabetes (and other endocrine abnormalities), and liver cirrhosis | Restrictive physiology                                                              |
|                          |                                                                                | CMR: rapid signal decay (<20 ms) on T2* imaging may guide venesection and/or iron chelation therapy |
|                          |                                                                                | Genetics: HFE gene testing (autosomal recessive)                                     |
|                          |                                                                                | Laboratory: total body iron studies and additional investigations to evaluate complications from multi-organ iron deposition |

Continued
| Condition | Clinical pearls | Diagnostic pointers |
|-----------|----------------|---------------------|
| Unclassified cardiomyopathies | **Left ventricular non-compaction** | Familial in up to 25% of cases<br>Also observed in other cardiomyopathies<br>Typical presentation with triad of palpitations, thrombo-embolism, and/or heart failure | ECG: LVH, supra-ventricular arrhythmias<br>Echo: by definition, ratio of non-compacted to compacted myocardium > 2:1. Colour flow Doppler demonstration of deep perfused intertrabecular sinuses<br>CMR: tendency to over diagnose condition<br>Genetics: autosomal dominant in familial cases<br>Laboratory: nil specific |
| Metabolic disorders | **Fabry disease** | Lysosomal storage disease<br>α-Galactosidase A deficiency<br>Multi-system disease<br>Enzyme replacement therapy available | ECG: LVH, short P–R interval (early stages), heart block (later stages)<br>Echo: predominant concentric LVH. Right ventricular and papillary muscle hypertrophy also common<br>CMR: late gadolinium enhancement in inferior LV wall<br>Genetics: absence of male–male transmission due to X-linked inheritance<br>Laboratory: proteinuria<br>Others: muscle biopsy |
| | **Pompe disease** | Glycogen storage disease (type II)<br>Acid maltase deficiency<br>Early onset: survival beyond 1 year uncommon<br>Later onset: can present in adulthood<br>Limb-girdle and respiratory muscle weakness<br>Enzyme replacement therapy available | ECG: LVH, short P–R interval (early stages), accessory pathways<br>Echo: concentric LVH with restrictive physiology<br>CMR: late gadolinium enhancement in inferior LV wall<br>Genetics: absence of male–male transmission due to X-linked inheritance<br>Laboratory: serum CK elevated, no fasting hypoglycaemia<br>Others: muscle biopsy |
| | **Danon disease** | Lysosomal glycogen storage disease with normal acid maltase<br>Lysosomal-associated membrane protein 2 (LAMP2) transporter protein deficiency<br>Males present in childhood, females in early adulthood<br>Skeletal muscle weakness and mental retardation | ECG: LVH, short P–R interval, accessory pathways<br>Echo: concentric LVH with restrictive physiology<br>CMR: late gadolinium enhancement in inferior LV wall<br>Genetics: autosomal recessive<br>Laboratory: normal acid maltase activity with reduced LAMP2 activity<br>Others: muscle biopsy |
| | **PRKAG2 cardiomyopathy** | Lysosomal glycogen storage disease<br>AMP-activated protein kinase g2 gene mutation<br>Multi-system involvement rare | ECG: LVH, short P–R interval, accessory pathways<br>Echo: concentric LVH with restrictive physiology<br>CMR: late gadolinium enhancement in inferior LV wall<br>Genetics: autosomal dominant<br>Laboratory: normal acid maltase activity with reduced LAMP2 activity<br>Others: muscle biopsy |
| | **Primary carnitine deficiency** | Fatty acid oxidation disorder<br>Functional carnitine transporter deficiency<br>Typically childhood presentation, but can present in adulthood<br>Skeletal muscle weakness, hepatomegaly, abnormal fatty acid metabolism | ECG: LVH<br>Echo: concentric LVH with restrictive physiology<br>CMR: nil specific<br>Genetics: autosomal recessive<br>Laboratory: hypoglycaemia, hyperammonaemia<br>Other: muscle biopsy: typical ragged red fibres |
| Mitochondrial myopathies | **Multiple varieties, e.g. Kearns-Sayre syndrome MERFF syndrome MELAS syndrome** | Characterized by skeletal weakness and mitochondrial disease<br>Cardiac: arrhythmias and LVH<br>Neurology: ataxia, stroke, dystagmus, ptosis, ophthalmoplegia, retinitis pigmentosa | ECG: LVH<br>Echo: concentric LVH with restrictive physiology<br>CMR: nil specific<br>Genetics: mitochondrial DNA mutation analysis<br>Laboratory: serum CK and glucose normal or elevated<br>Other: muscle biopsy: typical ragged red fibres |
| Syndromic conditions | **Noonan syndrome** | Common (up to 1:1000 live births). Sporadic or autosomal-dominant inheritance with mutations involving growth hormone proteins. Typically, facial dysmorphism, short stature, and cardiac abnormalities including LVH, pulmonary stenosis, septal defects<br>Friedreich’s ataxia: uncommon (up to 1:35 000 live births). Autosomal recessive with mutations involving proteins associated with mitochondrial iron metabolism. Typically, limb and gait ataxia, dysarthria, diabetes, and variable upper and lower motor neurone neuropathies of the lower limbs. Wheelchair bound in early adulthood. LVH presents in most cases |
of this cohort in fact had Fabry disease on further evaluation. This is clinically relevant since the management of these two diseases are different, and importantly, early identification, and treatment may alter the prognosis in Fabry disease.

**Fabry disease**

Fabry disease is an X-chromosome-linked disease of lysosomal metabolism resulting in attenuated activity or, in most males, absence of the enzyme \( \alpha \)-galactosidase A (\( \alpha \)-Gal A). As a result, the breakdown of glycosphingolipids is impaired leading to systemic lysosomal accumulation of globotriaosylceramide (Gb3). It is estimated that 1 in 40,000 males has Fabry disease, whereas the estimated prevalence in the general population is 1 in 117,000. Unlike many sex-linked disorders, the condition can affect both genders although its course is often less pronounced in women.

Genetic screening following diagnosis of a new index case can lead to the identification of additional family members with the Fabry gene. Most families have ‘private’ mutations found only in that family and the wide range of known mutations (hundreds of different mutations have been identified) may contribute to the variations in the residual enzyme activity and clinical presentation of Fabry disease. Multi-system morbidity commonly develops in childhood (Figure 1) and, with progression of the disease, life-threatening complications often occur in adulthood.

**Gender differences in Fabry disease**

The phenomenon of X-chromosome inactivation (i.e. permanent epigenetical silencing of one X-chromosome creating cellular mosaicism in females) may partly account for the disease presentation in females. Thus, although female Fabry patients may develop increased myocardial mass and LVH, the presentation of this manifestation is usually delayed by \( \approx \)10 years in comparison with male Fabry counterparts. In addition, while myocardial fibrotic scars (detectable by late enhancement imaging) are common in both genders with Fabry disease, scarring has been observed even in the non-hypertrophied stages of the disease in female patients.

Another important difference is that Fabry women are more likely than men to develop a cardiac variant characterized by isolated cardiac involvement only. Therefore, the threshold for offering gene testing in females suspected of Fabry disease should be low.

**Cardiac manifestations of Fabry disease**

**Globotriaosylceramide accumulation**

Globotriaosylceramide accumulation has been observed in vascular endothelial and smooth muscle cells, cardiomyocytes, conduction tissue and valvular fibroblasts. Although incompletely described, it is likely that inflammatory and neuro-hormonal mechanisms are involved in subsequent cellular and vascular dysfunction, leading to tissue ischaemia, hypertrophy, and fibrosis.

**Left ventricular hypertrophy**

Left ventricular hypertrophy is a key feature in Fabry disease and is reported in up to 50% of males and one-third of females. Conversely, among individuals with uncharacterized LVH, the Fabry gene has been identified in up to 4% of cases. In most cases the LVH is concentric; however, an asymmetrical variety with septal thickening and posterior wall fibrotic thinning may present in severe cases (Figure 2A). Right ventricular hypertrophy is also common and may progress to right ventricular dilatation.

**Myocardial fibrosis**

The fibrotic process in Fabry cardiomyopathy starts with intramural involvement with later transmural involvement. Fibrosis is
invariably present in the basal posterolateral segments. Cardiac magnetic resonance (CMR) is the imaging modality of choice in these cases (Figure 2B).

Conduction abnormalities and arrhythmias
Typical ECG findings include P–R interval shortening due to shortening of the P-wave duration. Later abnormalities include P–R interval prolongation, voltage signs of LVH, repolarization abnormalities, and atrio-ventricular block. Longitudinal studies suggest that arrhythmias occur in 27–42% of male and 27% of female patients with Fabry disease. Management of arrhythmias (including device therapies) should follow standard guidelines.  

Vascular abnormalities
Involvement of the coronary microcirculation can lead to angina (13–23% of patients), but myocardial infarction is uncommon (2% of patients). Arterial hypertension may result from renal insufficiency.

Extra-cardiac features of Fabry disease
Childhood symptoms (Figure 1) typically present between the ages of 5 and 10 years. Symptoms include: (i) small fibre neuropathic pain, chronic burning pain in hands and feet, recurrent severe limb pain triggered by fever, stress, physical activity or altered temperature, postprandial abdominal cramping, and diarrhoea, (ii) lack of sweating (hypohidrosis), (iii) thermal perception deficits with heat and exercise intolerance, (iv) whorl-like bilateral corneal opacities not affecting visual acuity (cornea verticillata, Figure 1: left panel), (v) small reddish/purple vascular lesions on the buttocks, groin, umbilicus, and upper thighs (angiokeratomata, Figure 1: right panel). Microalbuminuria may develop in young patients and is an antecedent to progressive Fabry nephropathy. Overt proteinuria and progressive decline in the glomerular filtration rate appear by the age of 20–30 years. Affected males typically progress to kidney failure by the fourth decade of life. Early stroke (ischaemic or haemorrhagic) has been reported in 6.9% of untreated males and 4.3% of females, occurring before the age of 30 years in one-fifth of the patients.

Diagnostic algorithm for Fabry disease
We propose a practical diagnostic approach to assist clinicians encountering undiagnosed Fabry patients presenting with LVH (Figure 3). After excluding common causes of LVH (Table 1) and faced with unexplained LVH, a stepwise approach is suggested.
First, the medical history is explored focusing on characteristic complications of Fabry disease. Red flags pointing towards a diagnosis of Fabry disease include the typical childhood symptoms described above, a family history of cardiomyopathy, chronic kidney disease, stroke, unexplained early death, or other signs/symptoms of Fabry disease. The absence of male-to-male transmission in the pedigree of a family burdened by LVH is a key feature of this X-linked disorder.

Physical examination may provide additional clues to Fabry disease, although in some cases multi-organ involvement may be absent. Angiokeratomata (Figure 1; right panel) and cornea verticillata (Figure 1; left panel) are typical clinical signs. Urine dipstick may reveal proteinuria, while the ECG may identify a short P–R interval.

Where Fabry disease is suspected, an α-Gal A enzyme activity assay in plasma or peripheral leucocytes should be performed. Most males completely lack lysosomal α-Gal A enzyme activity; however, a low level of residual α-Gal A (1–10% of normal) may be found in males with a late-onset cardiac phenotype. Interpretation of the enzyme assay in females is difficult since enzyme activity may be low normal or normal in up to one-third of the females with Fabry disease. Therefore, suspected female Fabry patients should undergo gene analysis as a first line test.

More recently, a dried blood spot enzyme assay has been introduced as a first-tier screening test for Fabry disease. The test involves placing whole blood droplets on absorbent filter paper with the advantage that samples can be stored for some weeks before posting to a central laboratory for batch testing.

Given the availability of an accurate diagnostic enzyme assay, cardiac biopsy is not generally required for diagnosing Fabry disease. The observation of cardiac cellular Gb₃ accumulation in patients undergoing cardiac biopsy during investigations for
unexplained restrictive cardiomyopathy may, however, be the first lead to the diagnosis of Fabry disease.17

Lately, gene testing for LVH has been gaining interest. Several commercial HCM genetic test panels including various sarcomere protein gene mutations and mutations causing metabolic disease (e.g. Fabry disease, Danon’s disease, and PRKAG2 cardiomyopathy) are available for diagnostic use, at least in the USA.18 In Europe, several hospital laboratories offer the possibility to screen for the most prevalent HCM genes (http://www.orpha.net). Inclusion of the Fabry disease-causing GLA gene should be recommended in the genetic screening of HCM patients, and in individuals not reporting Fabry symptoms and/or have a negative family history with otherwise unexplained LVH. Of note, a negative result of HCM genetic testing does not exclude the presence of HCM.

Once the Fabry mutation has been identified in an index patient, targeted mutation analysis can be used to diagnose at-risk males and females in that specific family. Genetically proven Fabry patients without phenotypic manifestations should undergo annual clinical follow-up. Information on genotype–phenotype correlations in Fabry disease is limited and, therefore, the decision to initiate enzyme replacement therapy (ERT) should be guided by the evaluation of signs, symptoms, and organ involvement.

**Enzyme replacement therapy**

The importance of recognizing Fabry disease lies in the availability of disease-modifying ERT. Two ERTs are currently available for Fabry disease; agalsidase alfa and agalsidase beta, both administered intravenously every other week. Prospective clinical trials have demonstrated that ERT can reduce the risk of major clinical events, remodel the LV, improve cardiac function, and increase exercise tolerance.9,19,20 Extra-cardiac benefits include; stabilization of renal function and improvement of peripheral pain. In addition, serial histological analyses of vascular endothelial cells in patients receiving ERT demonstrate that treatment is associated with intra-cellular Gb3 clearance.19 It has become increasingly clear that the severity of baseline hypertrophy and fibrosis determines the cardiac outcome with ERT, and that the best treatment outcomes can be obtained when treatment is started early.20

Once established, tissue and organ damage cannot be reversed. Thus, stabilization of the existing pathology, or slowing the progression to serious cardiac complications and improving survival, may be the most optimal outcome. Therefore, early diagnosis and screening relatives of confirmed cases is essential. Optimal care thus involves cascade screening and regular follow-up involving disease-specific and supportive treatments that are best served in the context of a multidisciplinary team.

**Conclusions**

Left ventricular hypertrophy remains a common pathology which requires exhaustive characterization. In most cases, LVH may be attributable to hypertension, valve disease, or obesity. It is important, however, not to miss potentially treatable conditions such as Fabry disease. Fabry disease is a progressive, multi-organ, genetic disease affecting both genders. Cardiac manifestations, including LVH and arrhythmias, are common and the cardiac complications are a key cause of premature death. We have proposed a practical approach to facilitate the identification of patients with otherwise unexplained LVH and Fabry disease. Confirmation of Fabry disease involves an enzyme activity assay in males and genetic testing in females. Once the mutation is known, extended family screening is important to identify unaffected relatives who may have the most to gain from ERT.

**Acknowledgements**

The authors acknowledge the editorial support of Hans Ebels, MD, from Genzyme Corporation. The authors maintain full and independent responsibility for the content of this manuscript.

**Funding**

Funding of the Open Access publication charges for this article was provided by Genzyme Europe BV.

**Conflict of interest:** Z.Y., F.C. and L.M. have received speakers fees from Genzyme Corporation. A.L., F.W., and P.E. have received travel grants and speakers fees from Genzyme Corporation and Shire HGT, B.E. has nothing to declare.

**References**

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–1566.
2. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Steward J, Shanewise JF, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography. J Am Soc Echocardiogr 2005;18:1440–1463.
3. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201–211.
4. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807–1816.
5. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kühf U, Masch B, McKenna WJ, Monserritt L, Pantuwiw S, Razepez C, Seferovic P, Tavazzi L, Keren A. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and peri-cardial diseases. Eur Heart J 2008;29:270–276.
6. Monserrett L, Gimeno-Blanes JR, Marin F, Hermita-Prieto M, Garcia-Honrubia A, Perez I, Fernandez X, de Nicolas R, de la Morena G, Paya E, Yague J, Egido J. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007;50:2399–2403.
7. Zarate YA, Hopkin R. Fabry’s disease. Lancet 2008;372:1427–1435.
8. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Bankazemi M, Feldt-Rasmussen U, Sims K, Walden S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lenmy RM, Germain DP. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112–128.
9. Weidemann F, Linhart A, Monserritt L, Strotmann J. Cardiac challenges in patients with Fabry disease. Int J Cardiol 2010;141:3–10.
10. Kampmann C, Linhart A, Baehner F, Paleck B, Wiethoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008;130:367–373.
11. Schrøder R, Warnock D, Bankazemi M, Bultas J, Lintnerh G, Padman S, Sorensen S, Wilcox W, Desnick R. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24:2102–2111.
12. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. *Stroke* 2009;40:788–794.

13. Niemann M, Hermann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. *JACC Cardiovasc Imaging* 2011;4:592–601.

14. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high risk populations: a systematic review. *J Med Genet* 2010;47:217–222.

15. Weidemann F, Sommer C, Duning T, Landl I, Mohrenschlager M, Nałęczynski D, Armig K, Baron R, Niemann M, Breunig F, Schaefer R, Strotmann J, Wanner C. Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge. *Am J Med* 2010;123:e651–e658.

16. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott PM. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. *Eur Heart J* 2007;28:1228–1235.

17. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, Levine GN, Narula J, Starling RC, Towbin J, Virmani R. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2007;28:3076–3093.

18. Wheeler M, Pavlovic A, DeGoma E, Salisbury H, Brown C, Ashley EA. A new era in clinical genetic testing for hypertrophic cardiomyopathy. *J Cardiovasc Transl Res* 2009;2:381–391.

19. Schaefer RM, Tylki-Szymańska A, Hilz MJ. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. *Drugs* 2009;69:2179–2205.

20. Weidemann F, Niemann M, Breunig F, Hermann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. *Circulation* 2009;119:524–529.